Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 2
1(33.3%)
3Total
N/A(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05466799Phase 2Active Not Recruiting

FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma

Role: lead

NCT06399172Not Yet Recruiting

OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy

Role: lead

NCT04493632Recruiting

OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.

Role: lead

NCT03003078Not ApplicableCompleted

A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane

Role: lead

NCT03076216Not ApplicableCompleted

A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With Gemcitabine +/- Nab-paclitaxel.

Role: lead

All 5 trials loaded